SBIR/STTR Research Award

Cryopreservation of Anopheles Embryos

Award identifier 4683d3849e0863fff5bd997aac667ba4a3bee351767b5355dfc3332ed4b28abaAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$2,477,711

Program and phase

SBIR · Phase II

Award year

2014

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
SANARIA INC.
Proposal award date
2014-08-25
Contract end date
2018-07-31
UEI
YLF2SS2NYGC5
Solicitation number
PA10-123
Topic code
R

Research abstract

DESCRIPTION provided by applicant The ideal most effective tool for eliminating Plasmodium falciparum Pf the causative agent of of all malaria deaths is a highly effective vaccine that prevents blood stage infection and thereby prevents both disease and transmission Sanariaandapos s goal is to develop and commercialize a Pf sporozoite SPZ vaccine that prevents Pf blood stage infection in andgt of recipients The Sanaria R PfSPZ Vaccine is composed of attenuated purified aseptic cryopreserved PfSPZ The platform technology developed to manufacture the vaccine has also facilitated the manufacture of PfSPZ for challenge infections to test vaccines and drugs PfSPZ Challenge and for vaccination by challenge under chemoprophylaxis PfSPZ CVac These comprise a portfolio of products that are on an aggressive timeline to commercialization Manufacture of all these PfSPZ products is dependent on Anopheles stephensi mosquitoes that can survive aseptic rearing from eggs to adults and produce high numbers andgt of PfSPZ in their salivary glands A vulnerable aspect of Sanariaandapos s manufacturing process is its reliance on mosquitoes that can only be maintained in colonies such colonies are susceptible to crashes and to genetic drift over time thereby being at risk of permanently losing the desired genotype and phenotype This is because despite decades of effort until our breakthrough achievement in Phase I live Anopheles could not be preserved in any way In Phase I we demonstrated new enabling technology the capability to cryopreserve eggs of A stephensi SDA strain In the GMP context being able to cryopreserve large lots of eggs will allow Sanaria to inaugurate controlled manufacturing by use of a Master Mosquito Bank thereby enabling us to return repeatedly to a repository stock generated from the same defined characterized material with the desired genetic background With careful management such a stock can last for many tens of years In this Phase II project we will fully optimize the cryopreservation method Specific Aim and use this method in scaled up production initially to ensure security of the colony for manufacturing purposes Specific Aim and subsequently for producing the larger Master Mosquito Egg Bank Specific Aim from which all mosquitoes used in manufacturing will be sourced Details of the characterized Master Mosquito Egg Bank will be submitted to the FDA as a Biologics Master File We will also systematically apply the egg cryopreservation technology to support development of improved strains of A stephensi and to create banks of eggs of such strains when developed Specific Aim Success in this project will have a critically important impact on Sanariaandapos s commercial success PUBLIC HEALTH RELEVANCE To protect individuals against malaria and to aid in eradicating this disease a highly effective vaccine is needed Sanaria has developed a platform technology the manufacture of live Plasmodium falciparum sporozoites PfSPZ to make such a vaccine Two are in clinical development The first is a live attenuated whole organism vaccine called the PfSPZ Vaccine which is currently being tested in a clinical trial at the Vaccine Research Center at the National Institutes of Health The second is a live infectious vaccine administered with an antimalarial drug a vaccine called PfSPZ CVac which will enter clinical trials later in In addition Sanaria has developed live infectious PfSPZ a product called PfSPZ Challenge for use in testing malaria drugs and vaccines This product is currently undergoing clinical trials to optimize dose and route of administration All the products require the growth of PfSPZ in aseptic Anopheles stephensi mosquitoes This proposal aims to preserve Sanariaandapos s genetic stock of A stephensi by optimizing methods for cryopreservation of mosquito embryos and scaling up the methods to allow rapid replacement of the mosquito colony and develop the first ever GMP Master Mosquito Bank The proposal will also support the huge international effort to release genetically modified mosquitoes GMM for malaria control by providing enabling technologies critical for the preservation of novel GMM lines and for the necessary scale up of mosquito rearing

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

61 SBIR/STTR records share this UEI (2003–2024). Reported award amounts total $99,330,850. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, Department of Defense

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.